Venture Capital Deals and Investments
  • All Technology
  • AI
  • Autonomy
  • B2B Growth
  • Big Data
  • BioTech
  • ClimateTech
  • Consumer Tech
  • Crypto
  • Cybersecurity
  • DevOps
  • Digital Marketing
  • Ecommerce
  • EdTech
  • Enterprise
  • FinTech
  • GovTech
  • Hardware
  • HealthTech
  • HRTech
  • LegalTech
  • Nanotech
  • PropTech
  • Quantum
  • Robotics
  • SaaS
  • SpaceTech
AllNewsDealsSocialBlogsVideosPodcastsDigests

Venture Capital Pulse

EMAIL DIGESTS

Daily

Every morning

Weekly

Sunday recap

NewsDealsSocialBlogsVideosPodcasts
NEOK Bio Secures $75M Series A Funding Led by ABL Bio
Series AVenture Capital

NEOK Bio Secures $75M Series A Funding Led by ABL Bio

•November 4, 2025
•Nov 4, 2025
0

Participants

Neok Bio

Neok Bio

company

ABL Bio

ABL Bio

investor

Why It Matters

The sizable funding accelerates NEOK Bio’s entry into the competitive ADC market, potentially reshaping cancer therapy with bispecific ADCs that could offer superior outcomes. Success could validate the bispecific ADC approach and attract further investment in next‑generation oncology biologics.

Deal Summary

NEOK Bio, a stealth-mode biotech focused on bispecific antibody‑drug conjugates, announced a $75 million Series A round. The financing is led by Korean biotech ABL Bio and will fund advancement of two ADC programs into clinical trials, targeting solid‑tumor indications by mid‑2026.

0

Comments

Want to join the conversation?

Loading comments...